Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Keith Alan Johnson, M.D.

Co-Author

This page shows the publications co-authored by Keith Johnson and Kathryn Papp.
Connection Strength

4.631
  1. Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease. Alzheimers Dement (Amst). 2021; 13(1):e12243.
    View in: PubMed
    Score: 0.247
  2. In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's disease pathology and cognitive decline. Sci Transl Med. 2021 09 22; 13(612):eabj2511.
    View in: PubMed
    Score: 0.246
  3. Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults. Neurology. 2021 04 06; 96(14):e1844-e1854.
    View in: PubMed
    Score: 0.236
  4. Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease. Alzheimers Dement (Amst). 2020; 12(1):e12132.
    View in: PubMed
    Score: 0.235
  5. The presubiculum links incipient amyloid and tau pathology to memory function in older persons. Neurology. 2020 05 05; 94(18):e1916-e1928.
    View in: PubMed
    Score: 0.223
  6. Word retrieval across the biomarker-confirmed Alzheimer's disease syndromic spectrum. Neuropsychologia. 2020 03 16; 140:107391.
    View in: PubMed
    Score: 0.220
  7. Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimers Dement. 2020 03; 16(3):552-560.
    View in: PubMed
    Score: 0.219
  8. Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurol. 2019 Aug 01; 76(8):915-924.
    View in: PubMed
    Score: 0.212
  9. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol. 2019 02; 85(2):181-193.
    View in: PubMed
    Score: 0.205
  10. Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia. J Alzheimers Dis. 2019; 67(2):757-768.
    View in: PubMed
    Score: 0.204
  11. Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci. 2018 03; 21(3):424-431.
    View in: PubMed
    Score: 0.192
  12. The relationship between recall of recently versus remotely encoded famous faces and amyloidosis in clinically normal older adults. Alzheimers Dement (Amst). 2018; 10:121-129.
    View in: PubMed
    Score: 0.189
  13. Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Ann Neurol. 2017 Apr; 81(4):583-596.
    View in: PubMed
    Score: 0.181
  14. Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance. Brain Imaging Behav. 2017 04; 11(2):383-390.
    View in: PubMed
    Score: 0.181
  15. Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology. 2017 Apr 11; 88(15):1431-1438.
    View in: PubMed
    Score: 0.180
  16. Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease. Neuropsychology. 2016 07; 30(5):624-30.
    View in: PubMed
    Score: 0.165
  17. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. Neuropsychologia. 2015 Jul; 73:169-75.
    View in: PubMed
    Score: 0.159
  18. Association of cortical microstructure with amyloid-ß and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. Mol Psychiatry. 2021 Sep 29.
    View in: PubMed
    Score: 0.062
  19. Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. Neurology. 2021 May 05.
    View in: PubMed
    Score: 0.060
  20. Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. Neurology. 2021 01 26; 96(4):e619-e631.
    View in: PubMed
    Score: 0.058
  21. Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. Alzheimers Res Ther. 2020 10 29; 12(1):138.
    View in: PubMed
    Score: 0.058
  22. Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. J Int Neuropsychol Soc. 2021 05; 27(5):426-438.
    View in: PubMed
    Score: 0.058
  23. The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2020 09 10; 12(1):104.
    View in: PubMed
    Score: 0.057
  24. Multiple markers contribute to risk of progression from normal to mild cognitive impairment. Neuroimage Clin. 2020; 28:102400.
    View in: PubMed
    Score: 0.057
  25. Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study. J Alzheimers Dis. 2020; 75(4):1437-1446.
    View in: PubMed
    Score: 0.055
  26. Decreased meta-memory is associated with early tauopathy in cognitively unimpaired older adults. Neuroimage Clin. 2019; 24:102097.
    View in: PubMed
    Score: 0.054
  27. Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. Alzheimers Dement (Amst). 2019 Dec; 11:670-678.
    View in: PubMed
    Score: 0.054
  28. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. JAMA Neurol. 2019 05 01; 76(5):542-551.
    View in: PubMed
    Score: 0.052
  29. An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults. J Alzheimers Dis. 2019; 68(3):1161-1170.
    View in: PubMed
    Score: 0.051
  30. Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity. J Neurosci. 2019 01 16; 39(3):548-556.
    View in: PubMed
    Score: 0.051
  31. Interactive Associations of Vascular Risk and ß-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study. JAMA Neurol. 2018 09 01; 75(9):1124-1131.
    View in: PubMed
    Score: 0.050
  32. Sex, amyloid, and APOE e4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimers Dement. 2018 09; 14(9):1193-1203.
    View in: PubMed
    Score: 0.049
  33. PET staging of amyloidosis using striatum. Alzheimers Dement. 2018 10; 14(10):1281-1292.
    View in: PubMed
    Score: 0.049
  34. Functional network integrity presages cognitive decline in preclinical Alzheimer disease. Neurology. 2017 Jul 04; 89(1):29-37.
    View in: PubMed
    Score: 0.046
  35. Neuroimaging markers associated with maintenance of optimal memory performance in late-life. Neuropsychologia. 2017 06; 100:164-170.
    View in: PubMed
    Score: 0.045
  36. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid ß. Alzheimers Dement. 2017 Sep; 13(9):1004-1012.
    View in: PubMed
    Score: 0.045
  37. Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study. J Alzheimers Dis. 2017; 59(3):975-985.
    View in: PubMed
    Score: 0.044
  38. Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. JAMA Neurol. 2016 Oct 01; 73(10):1185-1191.
    View in: PubMed
    Score: 0.044
  39. Harvard Aging Brain Study: Dataset and accessibility. Neuroimage. 2017 01; 144(Pt B):255-258.
    View in: PubMed
    Score: 0.039
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.